TOMAS GANZ, MD
Osteopathic Medicine at Century Blvd, Los Angeles, CA
License number
California G40227
Category
Osteopathic Medicine
Type
Pulmonary Disease
Address
Address
5767 W Century Blvd SUITE 200, Los Angeles, CA 90045
Phone
(310) 825-7499
(310) 825-6112
(310) 825-6112
Personal information
See more information about TOMAS GANZ at radaris.comName
Address
Phone
168 S Cliffwood Ave, Los Angeles, CA 90049
168 Cliffwood Ave, Los Angeles, CA 90049
1235 Alfred St, Los Angeles, CA 90035
Professional information
See more information about TOMAS GANZ at trustoria.com
Chief Medical Officer At Intrinsic Lifesciences Llc Professor At Ucla
Chief Medical Officer At Intrinsic Lifesciences Llc Professor At Ucla
Location:
Greater Los Angeles Area
Industry:
Research
Experience:
Intrinsic LifeSciences LLC (Privately Held; 1-10 employees; Biotechnology industry): Chief Medical Officer, (January 2007-Present) Iron- and anemia-related diagnosticsUCLA (Educational Institution; 10,001+ employees; Research industry): Professor, (1983-Pre...
Tomas Ganz, Los Angeles CA
Tomas Ganz, Los Angeles CA
Specialties:
Internal Medicine, Pulmonary Disease, Critical Care Medicine
Work:
Ucla Chs. 37 055
200 Medical Plz, Los Angeles, CA 90024 Ucla Chs. 37 055
10833 Le Conte Ave, Los Angeles, CA 90095
200 Medical Plz, Los Angeles, CA 90024 Ucla Chs. 37 055
10833 Le Conte Ave, Los Angeles, CA 90095
Education:
University of California at Los Angeles (1978)
Competitive Regulation Of Hepcidin Mrna By Soluble And Cell-Associated Hemojuvelin
Competitive Regulation Of Hepcidin Mrna By Soluble And Cell-Associated Hemojuvelin
US Patent:
7534764, May 19, 2009
Filed:
Jun 28, 2006
Appl. No.:
11/427095
Inventors:
Tomas Ganz - Los Angeles CA, US
Lan Lin - Los Angeles CA, US
Yigal P. Goldberg - Vancouver, CA
Lan Lin - Los Angeles CA, US
Yigal P. Goldberg - Vancouver, CA
Assignee:
The Regents of the University of California - Oakland CA
Xenon Pharmaceuticals, Inc. - Burnaby, British Columbia
Xenon Pharmaceuticals, Inc. - Burnaby, British Columbia
International Classification:
A61K 38/00
US Classification:
514 12
Abstract:
Disclosed herein are hemojuvelin-specific siRNAs that vary hemojuvelin mRNA concentration. Also disclosed herein, GPI-hemojuvelin positively regulated hepcidin mRNA expression, independently of the IL-6 pathway, whereas soluble hemojuvelin (s-hemojuvelin) suppressed hepcidin mRNA expression in primary human hepatocytes in a log-linear dosedependent manner. Disclosed are compositions and methods for modulating diseases of iron metabolism and hepcidin expression or hepcidin levels.
Cationic Oligopeptides Having Microbicidal Activity
Cationic Oligopeptides Having Microbicidal Activity
US Patent:
4705777, Nov 10, 1987
Filed:
Jun 28, 1985
Appl. No.:
6/750378
Inventors:
Robert I. Lehrer - Santa Monica CA
Michael E. Selsted - Los Angeles CA
Tomas Ganz - Los Angeles CA
Michael E. Selsted - Los Angeles CA
Tomas Ganz - Los Angeles CA
Assignee:
The Regents of the University of California - Berkeley CA
International Classification:
A61K 3702, C07K 710
US Classification:
514 12
Abstract:
Novel microbicidal compositions are provided which find use as preservatives, disinfectants, antigens and the like. Particularly, cationic oligopeptides of up to about thirty-five amino acids are provided having amino acid sequences substantially comparable to the amino acid sequences of cationic oligopeptides produced by macrophage. A conserved framework structure is provided.
Competitive Regulation Of Hepcidin Mrna By Soluble And Cell-Associated Hemojuvelin
Competitive Regulation Of Hepcidin Mrna By Soluble And Cell-Associated Hemojuvelin
US Patent:
7745407, Jun 29, 2010
Filed:
Mar 4, 2009
Appl. No.:
12/397589
Inventors:
Tomas Ganz - Los Angeles CA, US
Lan Lin - Beijing, CN
Yigal P. Goldberg - Vancouver, CA
Lan Lin - Beijing, CN
Yigal P. Goldberg - Vancouver, CA
Assignee:
The Regents of the University of California - Oakland CA
Xenon Pharmaceuticals Inc. - Burnaby, British Columbia
Xenon Pharmaceuticals Inc. - Burnaby, British Columbia
International Classification:
C12Q 1/68, A61K 38/00
US Classification:
514 12, 435 6
Abstract:
Disclosed herein are hemojuvelin-specific siRNAs that vary hemojuvelin mRNA concentration. Also disclosed herein, GPI-hemojuvelin positively regulated hepcidin mRNA expression, independently of the IL-6 pathway, whereas soluble hemojuvelin (s-hemojuvelin) suppressed hepcidin mRNA expression in primary human hepatocytes in a log-linear dosedependent manner. Disclosed are compositions and methods for modulating diseases of iron metabolism and hepcidin expression or hepcidin levels.
Defensin Peptide Compositions And Methods For Their Use
Defensin Peptide Compositions And Methods For Their Use
US Patent:
5242902, Sep 7, 1993
Filed:
Sep 6, 1989
Appl. No.:
7/404249
Inventors:
Christopher J. Murphy - Davis CA
Ted W. Reid - Davis CA
Mark J. Mannis - Carmichael CA
Bradley A. Foster - Davis CA
James S. Cullor - Woodland CA
Michael E. Selsted - Los Angeles CA
Robert I. Lehrer - Santa Monica CA
Tomas Ganz - Los Angeles CA
Ted W. Reid - Davis CA
Mark J. Mannis - Carmichael CA
Bradley A. Foster - Davis CA
James S. Cullor - Woodland CA
Michael E. Selsted - Los Angeles CA
Robert I. Lehrer - Santa Monica CA
Tomas Ganz - Los Angeles CA
Assignee:
The Regents of the University of California - Oakland CA
International Classification:
A61K 3702, A61K 3700, C07K 710
US Classification:
514 12
Abstract:
A method for treating cutaneous and corneal wounds as well as certain microbial-related diseases comprises topically applying a defensin peptide to the affected tissue. The compositions comprise a natural, synthetic, or analog defensin molecule having both a mitogenic activity capable of stimulating cell growth and an antimicrobial activity capable of inhibiting the growth of a wide variety of pathogens. In addition to therapeutic use, the defensins are useful as mitogens in cell and tissue culture media.
Use Of Antimicrobial Proteins And Peptides For The Treatment Of Otitis Media And Paranasal Sinusitis
Use Of Antimicrobial Proteins And Peptides For The Treatment Of Otitis Media And Paranasal Sinusitis
US Patent:
7985729, Jul 26, 2011
Filed:
Apr 21, 2010
Appl. No.:
12/764852
Inventors:
David J. Lim - Pasadena CA, US
Paul Webster - Pasadena CA, US
Ali Andalibi - Altadena CA, US
Jian-Dong Li - Glendale CA, US
Tomas Ganz - Los Angeles CA, US
Kiweon Cha - Irvine CA, US
Paul Webster - Pasadena CA, US
Ali Andalibi - Altadena CA, US
Jian-Dong Li - Glendale CA, US
Tomas Ganz - Los Angeles CA, US
Kiweon Cha - Irvine CA, US
Assignee:
House Research Institute - Los Angeles CA
International Classification:
A61P 31/04, A61K 38/17, C07K 14/435
US Classification:
514 24, 514 213, 530300
Abstract:
The pharmaceutical composition and a method of treatment of infectious diseases, such as otitis media, paranasal sinusitis, labyrinthitis and meningitis are described. The composition comprises EP2E or homologues thereof.
Competitive Regulation Of Hepcidin Mrna By Soluble And Cell-Associated Hemojuvelin
Competitive Regulation Of Hepcidin Mrna By Soluble And Cell-Associated Hemojuvelin
US Patent:
2010029, Nov 18, 2010
Filed:
May 6, 2010
Appl. No.:
12/775032
Inventors:
TOMAS GANZ - LOS ANGELES CA, US
LAN LIN - BEIJING, CN
YIGAL P. GOLDBERG - VANCOUVER, CA
LAN LIN - BEIJING, CN
YIGAL P. GOLDBERG - VANCOUVER, CA
International Classification:
A61K 38/17, C07K 14/435, G01N 33/68, C12N 15/63, C12N 5/07, A61P 3/00, A61P 3/02
US Classification:
514 212, 530350, 436 86, 4353201, 435325
Abstract:
Disclosed herein are hemojuvelin-specific siRNAs that vary hemojuvelin mRNA concentration. Also disclosed herein, GPI-hemojuvelin positively regulated hepcidin mRNA expression, independently of the IL-6 pathway, whereas soluble hemojuvelin (s-hemojuvelin) suppressed hepcidin mRNA expression in primary human hepatocytes in a log-linear dosedependent manner. Disclosed are compositions and methods for modulating diseases of iron metabolism and hepcidin expression or hepcidin levels.
Use Of Antimicrobial Proteins And Peptides For The Treatment Of Otitis Media And Paranasal Sinusitis
Use Of Antimicrobial Proteins And Peptides For The Treatment Of Otitis Media And Paranasal Sinusitis
US Patent:
2009002, Jan 22, 2009
Filed:
Jul 16, 2008
Appl. No.:
12/174577
Inventors:
David J. Lim - Pasadena CA, US
Paul Webster - Pasadena CA, US
Ali Andalibi - Altadena CA, US
Jian-Dong Li - Glendale CA, US
Tomas Ganz - Los Angeles CA, US
Kiweon Cha - Irvine CA, US
Paul Webster - Pasadena CA, US
Ali Andalibi - Altadena CA, US
Jian-Dong Li - Glendale CA, US
Tomas Ganz - Los Angeles CA, US
Kiweon Cha - Irvine CA, US
Assignee:
House Ear Institute - Los Angeles CA
International Classification:
C07K 14/00
US Classification:
530324
Abstract:
The pharmaceutical composition and a method of treatment of infectious diseases, such as otitis media, paranasal sinusitis, labyrinthitis and meningitis are described. The composition comprises EP2E or homologues thereof.
Mini-Hepcidin Peptides And Methods Of Using Thereof
Mini-Hepcidin Peptides And Methods Of Using Thereof
US Patent:
8435941, May 7, 2013
Filed:
Dec 4, 2009
Appl. No.:
13/131792
Inventors:
Tomas Ganz - Los Angeles CA, US
Elizabeta Nemeth - Los Angeles CA, US
Gloria Preza - Los Angeles CA, US
Piotr Pawel Ruchala - Los Angeles CA, US
Elizabeta Nemeth - Los Angeles CA, US
Gloria Preza - Los Angeles CA, US
Piotr Pawel Ruchala - Los Angeles CA, US
Assignee:
The Regents of the University of California - Oakland CA
International Classification:
A61K 38/04
US Classification:
514 54, 514 135, 514 218, 514 217, 514 216
Abstract:
Disclosed herein are peptides which exhibit hepcidin activity and methods of making and using thereof.